At 5.3% CAGR, the Europe Laboratory Animal Diet Market is projected to be worth US$ 1,882.51 million by 2028, says Business Market Insights 

According to Business Market Insights’ research, the Europe laboratory animal diet market was valued at US$ 1,390.14 million in 2022 and is expected to reach US$ 1,882.51 million by 2028, registering a CAGR of 5.3% from 2022 to 2028.  Rising usage of mice models in virology and infectious diseases and growing consumption of personalized medicines are the critical factors attributed to the market expansion.                

Mice models are essential tools for studying the pathogenesis of infectious diseases and for the preclinical evaluation of vaccines and therapies against various human pathogens. The use of genetically defined inbred mouse strains, humanized mice, and gene knockout mice has enabled the research community to study how pathogens cause diseases and explain the role of specific host genes in controlling or promoting diseases. It also helps determine potential targets for prevention or identification of treatments for various infectious agents. With the emergence of new infectious diseases, the animal model has become a vital tool for studying disease mechanisms and developing therapeutics. Mice with xenografted human immune systems have been used to study the pathogenesis of various infectious agents, including Plasmodium falciparum (malaria), Mycobacterium tuberculosis, dengue virus, and influenza virus. These models have been beneficial in studying HIV, which includes analyzing viral and host factors that promote viral replication and HIV interactions with the host's immune response. They are also helpful as platforms for testing therapeutic approaches to control HIV infection. Mouse models are widely used for preclinical screening of vaccines/therapies because of their reproducibility, low cost, and ease of experimental manipulation. Over the past century, advancements in vaccines, antibiotics/antivirals, and infection control measures have significantly reduced the burden of infectious diseases on public health. However, there has been an increase in contagious viral diseases. Mouse models are considered the best small animal models to be tested for hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, SARS-CoV-2, and cytomegalovirus (CMV). According to the WHO, more than 17 million people die from infectious diseases yearly. Over the past two decades, over 30 new infectious diseases have emerged. According to UNAIDS, 38 million people were affected by HIV by the end of 2019. Mouse models have been widely used for various viral studies due to their small size, low cost, ease of use, and high reproducibility. To study the effect of the vaccines and therapies, these mice models are given a particular standardized diet according to the need of the mice model. The prevalence of viral and infectious disease is driving the growth of the overall mice models due to which there is requirement of specific diet for the mice models. This is driving the growth of the Laboratory Animal Diet market.

On the contrary, high cost of laboratory animal diets due to maintenance and wastage hurdles the growth of Europe laboratory animal diet market.    

Based on diet type, the Europe laboratory animal diet market is segmented into standard diets, irradiated diets, and autoclavable diets. The standard diets segment held 62.7% market share in 2022, amassing US$ 871.36 million. It is projected to garner US$ 1,176.63 million by 2028 to expand at 5.1% CAGR during 2022–2028.  

Based on animal, the Europe laboratory animal diet market is segmented into mouse, cat, dog, rabbit, chicken, and others. The mouse segment held 45.3% market share in 2022, amassing US$ 629.55 million. It is projected to garner US$ 870.40 million by 2028 to expand at 5.5% CAGR during 2022–2028.

Based on application, the Europe laboratory animal diet market is segmented into drug discovery and personalized medicines, regenerative medicines, pathology of infectious disease, drug toxicity and efficacy testing, and others. The drug discovery and personalized medicine segment held 48.0%market share in 2022, amassing US$ 667.81 million. It is projected to garner US$ 884.21 million by 2028 to expand at 4.8% CAGR during 2022–2028.

Based on end user, the Europe end user market is segmented into pharmaceutical & biopharmaceutical companies, research & academic institutes, and others. The pharmaceutical & biopharmaceutical companies segment held 58.7% market share in 2022, amassing US$ 815.81 million. It is projected to garner US$ 1,092.46 million by 2028 to expand at 5.0% CAGR during 2022–2028.   

Based on country, the Europe laboratory animal diet market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% market share in 2022. It was assessed at US$ 409.40 million in 2022 and is likely to hit US$ 541.98 million by 2028, exhibiting a CAGR of 4.8% during the forecast period.    

Key players dominating the Europe laboratory animal diet market are Altromin Spezialfutter GmbH & Co. KG, Bio-Serv, Envigo, Krishna Valley Agrotech LLP, LabDiet, Research Diets Inc., SAFE, Special Diet Services, and Specialty Feeds among others.  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com